Cepheid:市場シェア分析...市場調査レポートについてご紹介

【英文タイトル】Cepheid Market Share Analysis

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 What Is This Report About? 11
3 Definitions of Markets/Categories Covered 12
3.1 In Vitro Diagnostics 12
3.1.1 Genetic Testing 12
3.1.2 Infectious Immunology 12
4 Company Snapshot 13
4.1 Key Facts 2011 13
4.2 Company Overview 13
4.3 Financial Performance 13
4.4 SWOT Snapshot 13
4.5 Business Overview 14
4.6 Major Products and Services 15
4.6.1 Overview 15
5 History 17
6 SWOT Analysis 19
6.1 Overview 19
6.2 Cepheid Strengths 19
6.2.1 Increasing Liquidity Ratios 19
6.2.2 The GeneXpert System 19
6.2.3 Strong In-house Research Expertise 20
6.2.4 Wide Market Applications 20
6.3 Cepheid Weaknesses 21
6.3.1 Termination of Supply Agreement with Roche 21
6.3.2 Product Recalls 21
6.3.3 Legal Proceedings 21
6.4 Cepheid Opportunities 22
6.4.1 Growth in Emerging Economies 22
6.4.2 Changing Demographics 22
6.4.3 New Product Launches and License Approvals 22
6.4.4 Inorganic Growth Strategies 22
6.5 Cepheid Threats 23
6.5.1 Cost Containment Pressures 23
6.5.2 Competitive Pressures 23
6.5.3 Government Regulations 23
6.5.4 Rapid Technological Advancements 23
7 Competitors 24
8 Competitive Landscape 25
8.1 In Vitro Diagnostics (Genetic Testing), Global, Market Share (%), 2011 25
8.2 Cepheid, In Vitro Diagnostics (Genetic Testing), by Region, Market Share (2011) 27
8.3 Cepheid, In Vitro Diagnostics (Genetic Testing), by Country, Market Share (2011) 28
8.4 In Vitro Diagnostics (Infectious Immunology), Global, Market Share (%), 2011 29
8.5 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Region, Market Share (2011) 31
8.6 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Country, Market Share (2011) 32
9 Cepheid Medical Equipment Market Share Analysis by Category 33
9.1 Cepheid, In Vitro Diagnostics, Global, Category Revenue Share (2011) 33
9.2 Cepheid, North America, Category Revenue Share (2011) 35
9.2.1 Cepheid, United States, Category Revenue Share (2011) 37
10 Key Employees 39
11 Key Employee Biographies 40
12 Company Statement 41
13 Locations And Subsidiaries 42
13.1 Head Office 42
13.2 Other Locations & Subsidiaries 42
14 Financial Deals Landscape 43
14.1 Cepheid, Deals Volume Summary, 2007 to YTD 2013 43
15 Cepheid Detailed Deal Summary 45
15.1 Partnerships 45
15.1.1 Cepheid Enters Into Licensing Agreement With Quantovir 45
15.1.2 Cepheid Enters Into Co-Development Agreement With FIND 46
15.1.3 Cepheid Enters Into Collaboration With Novartis 47
15.1.4 Prodesse Enters Into Distribution Agreement With Cepheid 48
15.1.5 Cepheid Enters Into Agreement With Instrumentation Lab 49
15.1.6 Biomerieux Enters Into An Agreement With Cepheid 50
15.2 Acquisition 51
15.2.1 Cepheid Acquires Stretton Scientific 51
15.2.2 Nycomed Sells Its Interest In Sangtec Molecular Diagnostic To Cepheid 52
16 Recent Developments 54
16.1 Financial Announcements 54
16.1.1 Oct 18, 2012: Cepheid Reports Revenue Of $80.6m In Q3 2012 54
16.1.2 Jul 19, 2012: Cepheid Reports Revenue Of $81m In Q2 2012 54
16.1.3 Apr 19, 2012: Cepheid Reports Revenue Of $77.3m In Q1 2012 55
16.1.4 Jan 26, 2012: Cepheid Reports Revenue Of $277.6m In 2011 55
16.1.5 Oct 20, 2011: Cepheid Reports Total Revenues Of $70.2m In Q3 2011 56
16.1.6 Jul 21, 2011: Cepheid Reports Total Revenues Of $67m In Q2 2011 56
16.1.7 Apr 20, 2011: Cepheid Reports Total Revenues Of $60.2m In Q1 2011 57
16.1.8 Jan 27, 2011: Cepheid Reports Total Revenues Of $212.46 Million In 2010 57
16.1.9 Oct 21, 2010: Cepheid Reports Total Revenues Of $56.05 Million In Q3 2010 58
16.1.10 Jul 22, 2010: Cepheid Reports Total Revenues Of $49.64 Million In Q2 2010 58
16.1.11 Apr 22, 2010: Cepheid Reports Total Revenues Of $48 Million In Q1 2010 59
16.1.12 Jan 28, 2010: Cepheid Reports Total Revenues Of $170.6 Million In 2009 59
16.1.13 Oct 28, 2009: Cepheid Reports Revenues Of $41.6 Million In Q3 2009 59
16.1.14 Jul 30, 2009: Cepheid Reports Total Revenues Of $41.02 Million In Q2 2009 60
16.1.15 Apr 23, 2009: Cepheid Posts Net Loss Of $7.4 Million, Revenues Of $44.8 million For Q1 2009 61
16.1.16 Feb 05, 2009: Cepheid Reports 2008 Results 61
16.1.17 Jan 13, 2009: Cepheid Reports Preliminary 2008 Results 62
16.1.18 Jan 13, 2009: Cepheid To Declare Full Year 2008 Results 62
16.1.19 Oct 28, 2008: Cepheid Reports 3Q 2008 Results 62
16.1.20 Oct 28, 2008: Cepheid Reports Third Quarter Revenue Of $44.9 Million 63
16.1.21 Oct 03, 2008: Cepheid To Report 3Q 2008 Results 64
16.1.22 Jul 24, 2008: Cepheid Reports 2Q 2008 Results 64
16.1.23 Jul 24, 2008: Cepheid Reports Second Quarter Revenue Of $42.1 Million 65
16.1.24 May 01, 2008: Cepheid Reports Q1 2008 Results 66
16.1.25 May 01, 2008: Cepheid Reports Record Revenue Of $44.8 Million 67
16.1.26 Apr 07, 2008: Cepheid To Report Q1 2008 Results 69
16.1.27 Feb 28, 2008: Cepheid Reports Q4 2007 Results 69
16.1.28 Feb 28, 2008: Cepheid Reports Fourth Quarter And Full Year 2007 Results 71
16.1.29 Nov 01, 2007: Cepheid Reports Third Quarter 2007 Results 73
16.1.30 Nov 01, 2007: Cepheid Reports Q3 2007 Results 73
16.1.31 Aug 07, 2007: Cepheid Reports Q2 2007 Results 75
16.1.32 Aug 07, 2007: Cepheid Reports Second Quarter 2007 Results 76
16.1.33 May 03, 2007: Cepheid Reports Q1 2007 Results 77
16.1.34 May 03, 2007: Cepheid Reports First Quarter 2007 Results 78
16.1.35 Feb 22, 2007: Cepheid Reports Q4 2006 Results 80
16.1.36 Feb 22, 2007: Cepheid Reports Fourth Quarter And Full Year 2006 Results 82
16.1.37 Nov 02, 2006: Cepheid Reports Q3 2006 Results 83
16.1.38 Nov 02, 2006: Cepheid Reports Third Quarter 2006 Results 85
16.1.39 Aug 08, 2006: Cepheid Reports Second Quarter 2006 Results 86
16.1.40 May 04, 2006: Cepheid Reports First Quarter 2006 Results 88
16.1.41 Feb 22, 2006: Cepheid Reports Fourth Quarter 2005 Results 90
16.1.42 Nov 03, 2005: Cepheid Reports Third Quarter 2005 Results 92
16.1.43 Aug 04, 2005: Cepheid Reports Second Quarter 2005 Results 93
16.1.44 May 04, 2005: Cepheid Reports First Quarter 2005 Results 95
16.1.45 Feb 28, 2005: Cepheid Reports Fourth Quarter And Fiscal Year 2004 Results 97
16.1.46 Nov 02, 2004: Cepheid Reports Third Quarter And Nine Months 2004 Results 99
16.1.47 Aug 04, 2004: Cepheid Reports Second Quarter And Six Months 2004 Results 100
16.1.48 May 05, 2004: Cepheid Reports First Quarter 2004 Results 102
16.1.49 Feb 17, 2004: Cepheid Reports Fourth Quarter And Fiscal Year 2003 Results 104
16.1.50 Jan 29, 2004: Cepheid Reports Preliminary Financial Results For Fourth Quarter And Fiscal Year 2003 106
16.1.51 Nov 04, 2003: Cepheid Reports Third Quarter And Nine Months 2003 Results 106
16.1.52 Jul 31, 2003: Cepheid Reports Second Quarter And Six Months 2003 Financial Results 108
16.1.53 Apr 30, 2003: Cepheid Reports First Quarter 2003 Results 110
16.1.54 Feb 05, 2003: Cepheid Reports Fourth Quarter And Full Year 2002 Results 111
16.1.55 Nov 06, 2002: Cepheid Reports Third Quarter 2002 Results 113
16.1.56 Jul 15, 2002: Cepheid Reports Second Quarter 2002 Financial Results 114
16.1.57 Apr 23, 2002: Cepheid Reports First Quarter 2002 Results 116
16.1.58 Feb 05, 2002: Cepheid Reports Fourth Quarter 2001 Results. 117
16.1.59 Oct 23, 2001: Cepheid Reports Third Quarter 2001 Results 118
16.1.60 Jul 24, 2001: Cepheid Reports Second Quarter 2001 Results 119
16.1.61 Apr 23, 2001: Cepheid Reports First Quarter 2001 Results 120
16.1.62 Feb 07, 2001: Cepheid Reports Fourth Quarter And Year End 2000 Results 122
16.1.63 Oct 23, 2000: Cepheid Reports Third Quarter Results 123
16.1.64 Jul 25, 2000: Cepheid Reports Second Quarter Results Initial Sales Of Smart Cycler Launched In May 124
16.2 Corporate Communications 125
16.2.1 Jun 22, 2011: Cepheid Appoints Robert Kwiatkowski As Vice President Of Infectious Disease R&D 125
16.2.2 Feb 28, 2011: Cepheid Appoints Michael Bates As Vice President Of Oncology Research And Development 125
16.2.3 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As EVP, Worldwide Commercial Operation 126
16.2.4 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As Executive Vice President Of Worldwide Commercial Operations 126
16.2.5 Feb 11, 2008: Cepheid Appoints SVP And CFO 127
16.2.6 Feb 07, 2006: Cepheid Appoints New Board Member 127
16.3 Legal and Regulatory 128
16.3.1 Sep 26, 2012: Abaxis Announces Settlement Of Patent Litigation With Cepheid 128
16.3.2 Jul 13, 2010: Cepheid Files Answer And Counterclaims In Abaxis Patent Suit 128
16.4 Product News 128
16.4.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 128
16.4.2 Aug 15, 2012: CCMC Selects Cepheid’s GeneXpert System 129
16.4.3 Aug 06, 2012: Cepheid Announces First Phase Of Xpert MTB/RIF Buy-Down For High Burden Developing Countries 130
16.4.4 Jul 25, 2012: Cepheid Announces Release Of Updated Xpert BCR-ABL Monitor Test 130
16.4.5 Jun 14, 2012: Cepheid Welcomes UNITAID Commitment To Broaden Access To Xpert MTB/RIF 131
16.4.6 May 24, 2012: Cepheid Receives FDA Clearance For GeneXpert Infinity-80 System For Initial Use With Xpert Flu Assay 132
16.4.7 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 132
16.4.8 May 23, 2012: Cepheid Receives CE Mark For Xpert CT/NG 132
16.4.9 Aug 09, 2011: Cepheid Releases Updated Xpert BCR-ABL Monitor Test 133
16.4.10 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 133
16.4.11 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 133
16.4.12 Dec 27, 2010: Cepheid Announces European Release Of Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 134
16.4.13 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 134
16.4.14 Jul 01, 2010: Cepheid Issues Recall Of Xpert MRSA/SA BC Product 135
16.4.15 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 135
16.4.16 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 136
16.4.17 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 136
16.4.18 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 137
16.4.19 Jun 17, 2009: Cepheid Releases Improved Xpert BCR-ABL Monitor Test In Europe 138
16.4.20 Apr 27, 2009: Cepheid Launches Xpert MTB/RIF Molecular Test In Europe 138
16.4.21 Mar 31, 2009: Cepheid Launches Xpert MRSA/SA Nasal Test In Europe 139
16.4.22 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 139
16.4.23 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 139
16.4.24 Nov 10, 2008: Cepheid Launches First On-Demand Molecular Diagnostic Test For Clostridium Difficile Into European Market 140
16.4.25 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 140
16.4.26 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 141
16.4.27 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 141
16.4.28 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 141
16.4.29 Jul 29, 2008: Cepheid Introduces GeneXpert Infinity-48 System At 2008 American Association Of Clinical Chemistry Meeting 142
16.4.30 Jul 28, 2008: Cepheid GeneXpert System Selected For Upto 11 Victoria, Australia Hospitals In Rollout Of Start Clean Strategy 142
16.4.31 Jul 28, 2008: Cepheid Xpert MRSA Selected In Rollout Of Start Clean Strategy 143
16.4.32 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico EV Test Menu In Canada And Mexico 143
16.4.33 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico GBS Test Menu In Canada And Mexico 143
16.4.34 Apr 03, 2008: Cepheid Selected As Vendor Of Choice By Connecticut Hospital Association Shared Services Program For Molecular MRSA Surveillance Testing 144
16.4.35 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 144
16.4.36 Jan 07, 2008: Cepheid Begins Shipment Of Next Generation GeneXpert Molecular Diagnostic Systems 145
16.4.37 Dec 04, 2007: Cepheid Launches New GeneXpert Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus 146
16.5 Product Approvals 146
16.5.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 146
16.5.2 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 147
16.5.3 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 147
16.5.4 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 147
16.5.5 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 148
16.5.6 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 148
16.5.7 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 149
16.5.8 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 149
16.5.9 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 150
16.5.10 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 150
16.5.11 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 151
16.5.12 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 151
16.5.13 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 151
16.5.14 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 152
16.5.15 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 152
16.6 Clinical Trials 153
16.6.1 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 153
16.7 Other Significant Developments 153
16.7.1 Jun 29, 2011: ‘Art Meets Innovation’ Event Teams Cepheid With Paul Jr Designs For Unveiling of New Products At 2011 AACC/ASCLS Meeting 153
16.7.2 May 18, 2011: Cepheid Signs Distribution Agreement With LABSCO In US 154
17 Appendix 155
17.1 Research Methodology 156
17.2 Secondary Research 156
17.3 Primary Research 156
17.4 Models 157
17.5 Forecasts 157
17.6 Expert Panels 157
17.7 GlobalData Consulting 157
17.8 Currency Conversion 158
17.9 Contact Us 159
17.10 Disclaimer 159


【レポート販売概要】

■ タイトル:Cepheid:市場シェア分析
■ 英文:Cepheid Market Share Analysis
■ 発行日:2013年2月15日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160379
■ 調査対象地域:グローバル
  • SM Energy Company:石油・ガスの開発・生産動向及びコスト分析– Q4, 2012
    SM Energy Company Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary SM Energy Company Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key …
  • 世界の個人高級品市場動向(2012-2016)
    TechNavio's analysts forecast the Global Personal Luxury Goods market to grow at a CAGR of 7.9 percent over the period 2012-2016. The growth of the Online Personal Luxury Goods market is one of the key factors contributing to the growth of the Global Personal Luxury Goods market. The Global Personal Luxury Goods market has also been witnessing the growth of the Accessories and Hard Luxury segment. …
  • ETC(電子料金収受システム)の世界市場
    The electronic toll collection system market report analyzes the key trends in the market on the basis of the demand in different applications such as highways and urban areas. The report provides an in-depth analysis of various developments in this market along with the key market trends. The market for electronic toll collection has been segmented on the basis of different technologies such as R …
  • Bio-Rad Laboratories, Inc.:市場シェア分析
    Bio-Rad Laboratories, Inc. Market Share Analysis Summary GlobalData’s new report, “Bio-Rad Laboratories, Inc. Market Share Analysis” provides in-depth information on Bio-Rad Laboratories, Inc.’s market position in the different medical equipment markets it operates in. The report provides Bio-Rad Laboratories, Inc. market share information in five key market categories – Microbiology Culture, Gene …
  • 腹膜炎(Peritonitis):世界の治験レビュー(2015年上半期版)
    Peritonitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Peritonitis Global Clinical Trials Review, H1, 2015" provides an overview of Peritonitis clinical trials scenario. This report provides top line data relating to the clinical trials on Peritonitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted acro …
  • 果物および野菜成分市場の世界市場:濃縮、ペースト・ピューレ、ストレートジュース、固形・粉末
    The global fruit & vegetable ingredients market is projected to grow at a CAGR of 6.6% from 2015 to reach a value of USD 201.67 Billion by 2020. The market is driven by factors such as increased demand for snacks & convenience food and beverages due to changing consumer preferences. Furthermore, factors such as increasing disposable income and rapid urbanization have also increased the demand for …
  • Petrominerales Ltd.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Petrominerales Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Petrominerales Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
  • BRIC(ブラジル・ロシア、インド、中国)の中小企業IT市場
    About SMB IT Spending in BRIC BRIC countries contributed approximately 38% of the global SMB IT spending in 2014. Technavio predicts that, in BRIC, SMB IT spending will cross $186 billion by 2019 from $111 billion in 2015. Over the past five years, IT spending priorities of SMBs have been redefined because of the growing awareness of the impact of IT on businesses, both top line and bottom line. T …
  • 摺動面油の世界市場分:製品別(ISO VG 68、ISO VG 220)、セグメント予測、2014-2025
    The global slideway oil market is expected to reach USD 94.78 billion by 2022, according to a new report by Grand View Research, Inc. High machinery demand in automobile, food & beverage and packaging industry is expected to fuel product market over the next seven years. Rapid industrialization in emerging economies of BRICS on account of favorable foreign investment norms, availability of large p …
  • 小売業向け物流サービスの世界市場
    About Retail Logistics Logistics is a process of planning, implementing, and controlling the operations of the supply chain activities to look upon the customer needs more efficiently. It involves planning and management of all activities involved in sourcing and procurement and in conversion of final products. The use of logistics in the Retail industry has led to low fulfillment costs, shorter d …
  • レベル3自動運転車の世界市場2017-2021
    About Level 3 Autonomous Vehicles An autonomous vehicle is a vehicle that is able to navigate and drive without any human intervention. This vehicle is equipped with an array of on-board sensors like LiDAR (light detection and ranging), radar, high resolution camera, sonars, laser scanners, and three dimensional (3D) cameras among others to gather and process information about its surroundings and …
  • 世界のトップ25バイオシミラー(バイオ後続品)メーカー分析2016-2026
    Biosimilar Drug Producers – Your 2016 Guide to Companies’ Activities and ProspectsWho are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations’ outlooks from 2016. There you see results, trends, opportunities and revenue forecasting. Visiongain’s new study analyses 25 leading developers, producers and market …
  • 脳内出血治療のグローバル臨床試験動向(2014年H2)
    Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Intracerebral Hemorrhage Global Clinical Trials Review, H2, 2014" provides data on the Intracerebral Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Intracerebral Hemorrhage. It includes an overview of the trial num …
  • 世界のスマートグリッド政策ハンドブック2016
    Smart Grid Policy Handbook 2016 Summary “Smart Grid Policy Handbook 2016” is the latest policy report from GlobalData, which offers comprehensive information on major policies governing smart grid in different countries. The report covers sixteen key countries, providing the current scenario and future plans in implementing smart grid technology, giving a fair idea of overall growth potential of t …
  • TVコンテンツホルダーのOTT戦略
    This report spotlights premium content right holders' strategies to tap the new internet territories. It provides a benchmark of OTT services launched by major rightholders. The study also provides the analyses and conclusions on these OTT strategies in highlighting their drivers and hurdles: technology, regulation, consumption patterns. Finally, it addresses the question of viability of an exclus …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。